free webpage hit counter

Subbiah reviews striking ASCO 2022 data across oncology

Subbiah reviews striking ASCO 2022 data across oncology

welcome to OncLive On Air®! I’m your host today, Caroline Seymour.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers all angles of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Vivek Subbiah, MD, about data presented at the 2022 ASCO Annual Meeting that caught his attention. Dr. Subbiah is an Associate Professor in the Investigational Cancer Therapeutics Department and the Center’s Clinical Medical Director at the Clinical Center for Targeted Therapy, Cancer Medicine Division, at the University of Texas MD Anderson Cancer Center.

In our exclusive interview, Dr Subbiah discussed findings from 4 presentations that stood out to him: phase 2 data (NCT04165772) showing a 100% complete response rate in 12 patients with repair-deficient, locally advanced rectal cancer receiving dostarlimab (Jemperli); DESTINY-Breast04 (NCT03734029), results he called “important and practice-changing” for patients with HER2-low unresectable and/or metastatic breast cancer; a first-in-human study (NCT04585750) of PC14586, a novel agent targeting mutated TP53 in advanced solid tumors; and the LIBRETTO-001 trial (NCT03157128), which showed that selpercatinib (Retevmo) can target RIGHT-positive fusions in solid tumors.

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the field of oncology.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

See also  PETER HOSKIN reviews Time Detectives - The Mystery Of The Mary Rose and Lego Atari 2600

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you enjoyed today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms* so you’ll be notified whenever a new episode is posted. While you’re there, please take a moment to rate us!

Thanks again for listening OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic and TuneIn.

You may also like...

Leave a Reply

Your email address will not be published.